禾元生物
(688765)
| 流通市值：0.00万 | | | 总市值：0.00万 |
| 流通股本：0.00万 | | | 总股本：0.00万 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 12,710,455.19 | 4,143,100 | 25,216,117.36 | 9,533,568.12 |
| 营业收入 | 12,710,455.19 | - | 25,216,117.36 | 9,533,568.12 |
| 二、营业总成本 | 104,059,673.66 | - | 194,140,323.14 | 98,645,931.27 |
| 营业成本 | 5,263,245.8 | - | 9,206,750.25 | 3,846,359.53 |
| 税金及附加 | 1,262,950.56 | - | 1,920,162.7 | 1,085,150.58 |
| 销售费用 | 2,695,026.46 | - | 4,467,215.28 | 2,490,325.41 |
| 管理费用 | 36,646,653.59 | - | 58,883,455.41 | 28,685,911.3 |
| 研发费用 | 55,936,535.09 | - | 116,786,228.31 | 61,798,556.25 |
| 财务费用 | 2,255,262.16 | - | 2,876,511.19 | 739,628.2 |
| 其中:利息费用 | 3,739,831.76 | - | 5,095,929.44 | 2,064,106 |
| 其中:利息收入 | 1,542,038.44 | - | 2,403,896.27 | 1,365,522.85 |
| 三、其他经营收益 | | | | |
| 资产处置收益 | 2,463,090.15 | - | -1,277,651.54 | -1,724,711.22 |
| 资产减值损失(新) | -368,217.96 | - | -477,417.72 | -436,293.95 |
| 信用减值损失(新) | -354,937.62 | - | -3,422.2 | -3,744.45 |
| 其他收益 | 7,981,468.06 | - | 19,314,578.01 | 12,685,074.63 |
| 营业利润平衡项目 | 0 | - | 0 | 0 |
| 四、营业利润 | -81,627,815.84 | - | -151,368,119.23 | -78,592,038.14 |
| 利润总额平衡项目 | 0 | - | 0 | 0 |
| 五、利润总额 | -81,627,815.84 | -48,195,200 | -151,368,119.23 | -78,592,038.14 |
| 六、净利润 | -81,627,815.84 | - | -151,368,119.23 | -78,592,038.14 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -81,627,815.84 | - | -151,368,119.23 | -78,592,038.14 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -81,627,815.84 | -48,195,200 | -151,368,119.23 | -78,592,038.14 |
| 扣除非经常损益后的净利润 | -90,535,300.05 | -48,808,700 | -166,747,441.91 | -87,866,238.14 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.3 | - | -0.56 | -0.29 |
| (二)稀释每股收益 | -0.3 | - | -0.56 | -0.29 |
| 九、综合收益总额 | -81,627,815.84 | - | -151,368,119.23 | -78,592,038.14 |
| 归属于母公司股东的综合收益总额 | -81,627,815.84 | - | -151,368,119.23 | -78,592,038.14 |
| 公告日期 | 2025-09-23 | 2025-06-24 | 2025-03-31 | 2024-12-31 |
| 审计意见(境内) | 标准无保留意见 | | 标准无保留意见 | 标准无保留意见 |